Phase I dose-escalation and -expansion study to evaluate safety and efficacy of capmatinib (INC280) in patients with advanced MET-dependent solid tumors
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.